Insights from bcl-2 and myc: Malignancy involves abrogation of apoptosis as well as sustained proliferation

Cancer Research

Volumn 59, Issue 7 SUPPL., 1999, Pages

  Cory, Suzanne ^a   Vaux, David L ^a   Strasser, Andreas ^a   Harris, Alan W ^a   Adams, Jerry M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

APOPTOSIS; BURKITT LYMPHOMA; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; CONFERENCE PAPER; HUMAN; LYMPHOCYTE TRANSFORMATION; LYMPHOMA; ONCOGENE MYC; PRIORITY JOURNAL; REGULATORY MECHANISM; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BURKITT LYMPHOMA; CELL CYCLE; CELL DIVISION; GENES, BCL-2; GENES, MYC; LYMPHOMA, FOLLICULAR; MALE; MICE; MICE, TRANSGENIC; MUTATION; SPERMATOGENESIS;

EID: 0033118755     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (99)

1. Nowell, P. C., and Hungerford, D. A. A minute chromosome in human chronic granulocytic leukemia. Science (Washington DC), 132: 1497, 1960.
2. Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond.), 243: 290-293, 1973.
3. Klein, G. The role of gene dosage and genetic transpositions in carcinogenesis. Nature (Lond.), 294: 313-318, 1981.
4. Cory, S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv. Cancer Res., 47: 189-234, 1986.
5. Adams, J. M., Gerondakis, S., Webb, E., Mitchell, J., Bernard, O., and Cory, S. Transcriptionally active DNA region that rearranges frequently in murine lymphoid tumors. Proc. Natl. Acad. Sci. USA, 79: 6966-6970, 1982.
6. Adams, J. M., Gerondakis, S., Webb, E., Corcoran, L. M., and Cory, S. Cellular myc oncogene is altered by chromosome translocation to an immunoglobulin locus in murine plasmacytomas and is rearranged similarly in human Burkitt lymphomas. Proc. Natl. Acad. Sci. USA, 80: 1982-1986, 1983.
7. Harris, L. J., Lang, R. B., and Marcu, K. B. Non-immunoglobulin-associated DNA rearrangements in mouse plasmacytomas. Proc. Natl. Acad. Sci. USA, 79: 4175-4179, 1982.
8. Calame, K., Kim, S., Lalley, P., Hill, R., Davis, M., and Hood, L. Molecular cloning of translocations involving chromosome 15 and the immunoglobulin C α gene from chromosome 12 in two murine plasmacytomas. Proc. Natl. Acad. Sci. USA, 79: 6994-6998, 1982.
9. Taub, R., Kirsch, I., Morton, C., Lenoir, G., Swan, D., Tronick, S., Aaronson, S., and Leder, P. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. USA, 79: 7837-7841, 1982.
10. Shen-Ong, G. L., Keath, E. J., Piccoli, S. P., and Cole, M. D. Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. Cell, 31: 443-452, 1982.
11. Dalla-Favera, R., Martinotti, S., Gallo, R. C., Erikson, J., and Croce, C. M. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science (Washington DC), 219: 963-967, 1983.
12. Ohno, S., Babonits, M., Wiener, F., Spira, J., Klein, G., and Potter, M. Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell, 18: 1001-1007, 1979.
13. Gerondakis, S., Cory, S., and Adams, J. M. Translocation of the myc cellular oncogene to the immunoglobulin heavy chain locus in murine plasmacytomas is an imprecise reciprocal exchange. Cell, 36: 973-982, 1984.
14. Bernard, O., Cory, S., Gerondakis, S., Webb, E., and Adams, J. M. Sequence of the murine and human cellular myc oncogenes and two modes of myc transcription resulting from chromosome translocation in B lymphoid tumours. EMBO J., 2: 2375-2383, 1983.
15. Hayward, W. S., Neel, B. G., and Astrin, S. M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. Nature (Lond.), 290: 475-480, 1981.
16. Corcoran, L. M., Adams, J. M., Dunn, A. R., and Cory, S. Murine T lymphomas in which the cellular myc oncogene has been activated by retroviral insertion. Cell, 37: 113-122, 1984.
17. Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., and Brinster, R. L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (Lond.), 318: 533-538, 1985.
18. Harris, A. W., Pinkert, C. A., Crawford, M., Langdon, W. Y., Brinster, R. L., and Adams, J. M. The Eμ-myc transgenic mouse: a model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med., 167: 353-371, 1988.
19. Schmidt, E. V., Pattengale, P. K., Weir, L., and Leder, P. Transgenic mice bearing the c-myc gene activated by an immunoglobulin enhancer: a pre-B cell lymphoma model. Proc. Natl. Acad. Sci. USA, 85: 6047-6051, 1988.
20. Harris, A. W., Langdon, W. Y., Alexander, W. S., Hariharan, I. K., Rosenbaum, H., Vaux, D., Webb, E., Bernard, O., Crawford, M., Abud, H., Adams, J. M., and Cory, S. Transgenic mouse models for hematopoietic tumorigenesis. Curr. Top. Microbiol. Immunol., 141: 82-93, 1988.
21. Webb, E., Adams, J. M., and Cory, S. Variant (6;15) translocation in a murine plasmacytoma occurs near an immunoglobulin K gene but far from the myc oncogene. Nature (Lond.), 312: 777-779, 1984.
22. Langdon, W Y., Harris, A. W., Cory, S., and Adams, J. M. The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice. Cell, 47: 11-18, 1986.
23. Alexander, W. S., Bernard, O., Cory, S., and Adams, J. M. Lymphomagenesis in Eμ-myc transgenic mice can involve ras mutations. Oncogene, 4: 575-581, 1989.
24. Land, H., Parada, L. F., and Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (Lond.), 304: 596-602, 1983.
25. Sinn, E., Muller, P., Pattengale, I., Tepler, R., Wallace, P., and Leder, F. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell, 49: 465-475, 1987.
26. Haupt, Y., Alexander, W. S., Barri, G., Klinken, S. P., and Adams, J. M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eμ-myc transgenic mice. Cell, 65: 753-763, 1991.
27. van Lohuizen, M., Verbeek, S., Scheijen, B., Wientjens, E., van der Gulden, H., and Berns, A. Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging. Cell, 65: 737-752, 1991.
28. Langdon, W. Y., Harris, A. W., and Cory, S. Growth of Eμ-myc transgenic B-lymphoid cells in vitro and their evolution toward autonomy. Oncogene Res., 3: 271-279, 1988.
29. Askew, D. S., Ashmun, R. A., Simmons, B. C., and Cleveland, J. L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene, 6: 1915-1922, 1991.
30. Evan, G. I., Wyllie, A. H., Gilbert, C. S., Litllewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
31. Rabbitts, T. H. Chromosomal translocations in human cancer. Nature (Lond.), 372: 143-149, 1994.
32. Tsujimoto, Y., Finger, L. R., Yunis, J., Nowell, P. C., and Croce, C. M. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (Washington DC), 226: 1097-1099, 1984.
33. H on chromosome 14 and near a transcriptional unit on 18. Cell, 41: 899-906, 1985.
34. Cleary, M. L., Smith, S. D., and Sklar, J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell, 47: 19-28, 1986.
35. Tsujimoto, Y., Ikegaki, N., and Croce, C. M. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene, 2: 3-7, 1987.
36. Monaghan, P., Robertson, D., Amos, T. A. S., Dyer, M. J. S., Mason, D. Y., and Greaves, M. F. Ultrastructural localization of BCL-2 protein. J. Histochem. Cytochem., 40: 1819-1825, 1992.
37. Vaux, D. L., Cory, S., and Adams, J. M. bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (Lond.), 335: 440-442, 1988.
38. McDonnell, T. J., Deane, N., Platt, F. M., Nuñez, G., Jaeger, U., McKearn, J. P., and Korsmeyer, S. J. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell, 57: 79-88, 1989.
39. Strasser, A., Whittingham, S., Vaux, D. L., Bath, M. L., Adams, J. M., Cory, S., and Harris, A. W. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc. Natl. Acad. Sci. USA, 88: 8661-8665, 1991.
40. Strasser, A., Harris, A. W., and Cory, S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell, 67: 889-899, 1991.
41. Sentman, C. L., Shutter, J. R., Hockenbery, D., Kanagawa, O., and Korsmeyer, S. J. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67: 879-888, 1991.
42. McDonnell, T. J., and Korsmeyer, S. J. Progression from lymphoid hyperplasia to high-grade malignant lyrnphoma in mice transgenic for the t(14;18). Nature (Lond.), 349: 254-256, 1991.
43. Strasser, A., Harris, A. W., and Cory, S. Eμ-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene, 8: 1-9, 1993.
44. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.
45. Strasser, A., Harris, A. W., Jacks, T., and Cory, S. DNA damage can induce apoplosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell, 79: 329-339, 1994.
46. Strasser, A., Harris, A. W., Bath, M. L., and Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and. bcl-2. Nature (Lond.), 348: 331-333, 1990.
47. Strasser, A., Elefanty, A. G., Harris, A. W., and Cory, S. Progenitor tumours from Eμ-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J., 15: 3823-3834, 1996.
48. Wiman, K. G., Magnusson, K. P., Ramqvist, T., and Klein, G. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene, 6: 1633-1639, 1991.
49. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D M., and Dalla-Favera, R. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88: 5413-5417, 1991.
50. Hsu, B., Marin, M. C., El-Naggar, A. K., Stephens, L. C., Brisbay, S., and McDonnell, T. J. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene, 11: 175-179, 1995.
51. Cory, S. Regulation of lymphocyte survival by the BCL-2 gene family. Annu. Rev. Immunol., 13: 513-543, 1995.
52. Vaux, D. L., and Strasser, A. The molecular biology of apoptosis. Proc. Natl. Acad. Sci. USA, 93: 2239-2244, 1996.
53. Strasser, A., Huang, D. C. S., and Vaux, D. L. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim. Biophys. Acta, 1333: F151-F178, 1997.
54. Adams, J. M., and Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science (Washington DC), 281: 1322-1326, 1998.
55. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell, 74: 609-619, 1993.
56. O'Connor, L., Strasser, A., O'Reilly, L. A., Hausmann, G., Adams, J. M., Cory, S., and Huang, D. C. S. Bim-a novel member of the Bcl-2 family that promotes apoptosis. EMBO J., 17: 384-395, 1998.
57. L, an inhibitor of programmed cell death. Nature (Lond.), 381: 335-341, 1996.
58. L-Bak peptide complex: recognition between regulators of apoptosis. Science (Washington DC), 275: 983-986, 1997.
59. Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C., and Perucho, M. Somatic frameshift mutations in the box gene in colon cancers of the microsatellite mutator phenotype. Science (Washington DC), 275: 967-969, 1997.
60. Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A., Mao, X., Nuñez, G., and Thompson, C. B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597-608, 1993.
61. Gibson, L., Holmgreen, S., Huang, D. C. S., Bernard, O., Copeland, N. G., Jenkins, N. A., Sutherland, G. R., Baker, E., Adams, J. M., and Cory, S. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene, 13: 665-675, 1996.
62. L and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene, 14: 405-414, 1997.
63. Veis, D. J., Sorenson, C. M., Shutter, J. R., and Korsmeyer, S. J. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell, 75: 229-240, 1993.
64. Motoyama, N., Wang, F. P., Roth, K. A., Sawa, H., Nakayama, K., Nakayama, K., Negishi, I., Senju, S., Zhang, Q., Fujii, S., and Loh, D. Y. Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science (Washington DC), 267: 1506-1510, 1995.
65. Ma, A., Pena, J. C., Chang, B., Margosian, E., Davidson, L., Alt, F. W., and Thompson, C. B. Bclx regulates the survival of double-positive thymocytes. Proc. Natl. Acad. Sci. USA, 92: 4763-4767, 1995.
66. Ross, A. J., Waymire, K. G., Moss, J.E., Parlow, A. F., Skinner, M. K., Russell, L. D., and MacGregor, G. R. Testicular degeneration in Bcl-w-deficient mice. Nat. Genet., 18: 251-256, 1998.
67. Print, C. G., Loveland, K. L., Gibson, L., Meehan, T., Stylianou, A., Wreford, N., de Kretser, D., Metcalf, D., Köntgen, F., Adams, J. A., and Cory, S. Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc. Natl. Acad. Sci. USA, 95: 12424-12431, 1998.
68. Ellis, H. M., and Horvitz, H. R. Genetic control of programmed cell death in the nematode C. elegans. Cell, 44: 817-829, 1986.
69. Conradt, B., and Horvitz, H. R. The C. elegans protein EGL-1 is required for programmed cell death and interacts with the Bcl-2-like protein CED-9. Cell, 93: 519-529, 1998.
70. Thornberry, N. A., and Lazebnik, Y. Caspases. Enemies within. Science (Washington DC), 281: 1312-1316, 1998.
71. Hengartner, M. O., ElliS, R. E., and Horvitz, H. R. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death. Nature (Lond.), 356: 494-499, 1992.
72. Vaux, D. L., Weissman, I. L., and Kim, S. K. Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. Science (Washington DC), 258: 1955-1957, 1992.
73. Hengartner, M. O., and Horvitz, H. R. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell, 76: 665-676, 1994.
74. Vaux, D. L., Haecker, G., and Stresser. A. An evolutionary perspective on apoptosis. Cell, 76: 777-779, 1994.
75. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Washington DC), 281: 1309-1311, 1998.
76. Vaux, D. L. CED-4-The third horseman of apoptosis. Cell, 90: 389-390, 1997.
77. Huang, D. C. S., Adams, J. M., and Cory, S. The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J., 17: 1029-1039, 1998.
78. Strasser, A., Harris, A. W., Huang, D. C. S., Krammer, P. H., and Cory, S. Bcl-2 and Fas/APO-I regulate distinct pathways to lymphocyte apoptosis. EMBO J., 14: 6136-6147, 1995.
79. Vaux, D. L., Aguila, H. L., and Weissman, I. L. Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. Int. Immunol., 4: 821-824, 1992.
80. Ashkenazi, A., and Dixit, V. M. Death receptors: signaling and modulation. Science (Washington DC), 281: 1305-1308, 1998.
81. Yoshida, H., Kong, Y-Y., Yoshida, R., Elia, A. J., Hakem, A., Hakem, R., Penninger, J. M., and Mak, T. W. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell, 94: 739-750, 1998.
82. Hakem, R., Hakem, A., Duncan, G. S., Henderson, J. T., Woo, M., Soengas, M. S., Elia, A., de la Pompa, J. L., Kagi, D., Khoo, W., Potter, J., Yoshida, R., Kaufman, S. A., and Lowe, S. W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell, 94: 339-352, 1998.
83. Newton, K., Harris, A. W., Bath, M. L., Smith, K. G. C., and Strasser, A. A dominant interfering mutant of FADD/Mort1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes. EMBO J., 17: 706-718, 1998.
84. Marvel, J., Perkins, G. R., Lopez-Rivas, A., and Collins, M. K. L. Growth factor starvation of bcl-2 overexpressing murine bone marrow cells induced refractoriness to IL-3 stimulation of proliferation. Oncogene, 9: 1117-1122, 1994.
85. O'Reilly, L., Huang, D. C. S., and Strasser, A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J., 15: 6979-6990, 1996.
86. Linette, G. P., Li, Y., Roth, K., and Korsmeyer, S. J. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc. Natl. Acad. Sci. USA, 93: 9545-9552, 1996.
87. Mazel, S., Burtrum, D., and Petrie, H. T. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J. Exp. Med., 183: 2219-2226, 1996.
88. O'Reilly, L. A., Harris, A. W., Tarlinton, D. M., Corcoran, L. M., and Strasser, A. Expression of a bcl-2 transgene reduces proliferation and slows turnover of developing B lymphocytes in vivo. J. Immunol., 159: 2301-2311, 1997.
89. - T cell progenitors. Int. Immunol., 9: 1291-1301, 1997.
90. Vairo, G., Innes, K. M., and Adams, J. M. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene, 13: 1511-1519, 1996.
91. Huang, D. C. S., O'Reilly, L. A., Strasser, A., and Cory, S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J., 16: 4628-4638, 1997.
92. Uhlmann, E. J., D'Sa-Eipper, C., Subramanian, T., Wagner, A. J., Hay, N., and Chinnadurai, G. Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: suppression of apoptosis with concomitant cell proliferation. Cancer Res., 56: 2506-2509, 1996.
93. Shibasaki, F., Kondo, E., Akagi, T., and McKeon, F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature (Lond.), 386: 728-731, 1997.
94. Matolcsy, A., Casali, P., Warnke, R. A., and Knowles, D. M. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood, 88: 3937-3944, 1996.
95. Cory, S., and Adams, J. M. Transgenic mice and oncogenesis. Annu. Rev. Immunol., 6: 25-48, 1988.
96. Adams, J. M., and Cory, S. Transgenic models of tumor development. Science (Washington DC), 254: 1161-1167, 1991.
97. Adams, J. M., and Cory, S. Transgenic models for haemopoietic malignancies. Biochim. Biophys. Acta, 1072: 9-31, 1991.
98. Metz, T., Harris, A. W., and Adams, J. M. Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes. Cell, 82: 29-36, 1995.
99. Jager, R., Herzer, U., Schenkel, J., and Weiher, H. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene, 15: 1787-1795, 1997.